The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company ...

[Lp(a)] inhibitor, HRS-5346. Currently in a Phase II trial in China, the therapy is intended to address cardiovascular diseases associated with elevated Lp(a) levels. MSD will pay Hengrui Pharma $200m ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself. If you’ve been around drug development ...

Overall survival was 19-20 months regardless of treatment arm, even in patients with PD-L1-positive tumors. This trial adds to multiple negative studies of immune checkpoint inhibitors in advanced ...

While they help prevent autoimmunity, many cancers exploit this pathway to evade immune detection. PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune ...